Verici Dx Plc · LSE:VRCI
Verici Dx — Corporate Update (March 2022)
20 slides from Verici Dx's corporate update, Mar 4, 2022
Slide 1: Corporate Update
Corporate Update January 2022
Slide 2: Disclaimer
DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA (THE "U.S.") (EXCEPT TO CERTAIN INVITED QIBS AND AIS (AS DEFINED BELOW), CANADA, AUSTRALIA, JAPAN OR ANY JURISD
Slide 3: Vision: An integrated platform yielding rich data asset for innovation
Vision: An integrated platform yielding rich data asset for innovation Data for Research Collaborations AUTO-IMMUNE DISEASES PRE-TRANSPLANT | EARLY-STAGE DAMAGE | LATE-STAGE DAMAGE Kidney Transplant Data-centric approach expected to increase the pace of OTHER ORGANS In-licensing, partnering or acqui
Slide 4: Update at a glance
Update at a glance Milestones Status Schedule Clarava Clinical Trial enrollment & endpoints Completed ✓ Ahead/On time ✓ Tuteva Clinical Trial enrollment & endpoints Completed ✓ Ahead/On time ✓ CLIA Lab approval Completed ✓ Ahead ✓ PLA codes } both products Completed ✓ Ahead ✓ Incremental Achievement
Slide 5: 3 foundational tests, enhanced end-to-end transplant testing for improved outcomes
3 foundational tests, enhanced end-to-end transplant testing for improved outcomes Pre-Transplant Prognostic Patients now can Post-Transplant Prognostic mRNA 14 gene Signature be prescribed mRNA 17 gene Signature treatment at an Advantages: Advantages: • Provides risk score for early acute appropria
Slide 6: Initial Products: Total addressable market circa $5bn over 5 years
Initial Products: Total addressable market circa $5bn over 5 years Pre-Transplant Evaluation Post-transplant Follow-up Addressable market increases with underlying growth $450 million p.a. $300 million p.a. and increased $1.5 bn supply $2.25bn over 5 years over 5 years Assumes 2 tests Assumes 3 test
Slide 7: The Clinical Trials in Organ Transplantation (CTOT) program
The Clinical Trials in Organ Transplantation (CTOT) program • NIH1 Funded: NIAID2 intends to commit $9.5 million • Influential decision makers: active Steering Committee yearly, to make 3 to 4 awards. with mechanistic and publication sub-committees • Total participation: 30 Transplant Centers • Addi
Slide 8: Potential build-out of the platform
Potential build-out of the platform PRE-TRANSPLANT | EARLY-STAGE DAMAGE | LATE-STAGE DAMAGE Existing suite New technology Other testing Other testing areas areas Dominate IVD kit format More appropriate pre-transplant + cloud-based than early-stage testing market software tool current offerings 8
Slide 9: Unparalleled data set for leading competitive advantage
Unparalleled data set for leading competitive advantage Next Generation Sequencing enables data capture on the Patient information samples and CLINICAL patient’s entire transcriptome BIOMARKERS therapeutic dosing information of about 25,000 genes DATA collected on a longitudinal basis Artificial Int
Slide 10: Acceleration in regulatory and reimbursement pathways
Acceleration in regulatory and reimbursement pathways Regulatory pathway Reimbursement Health Economics 1 2 3 LDT is the preferred route in this area Process: obtaining a code, a price and Model completion expected by (high complexity Lab). Approval ensuring coverage, usually in sequence end of Q1 2
Slide 11: Robust Clinical Pathway to revenues
Robust Clinical Pathway to revenues Initial endpoints All clinical Enrollment (early data) endpoints completed (data to follow) Validation trials Utility completed case studies Clarava: Clinical Clarava: Clinical completed utility enrollment utility endpoints completed (data to follow) Performance m
Slide 12: Financial Update
Financial Update • Original 2-product IPO forecast guidance indicated funding to mid 2023 with an expectation of additional funding in 2022 • Unaudited cash balance at 31 Dec 21 circa $10.3m • Revised Base Case projections show sufficient funding for expedited development of Protega, laboratory impr
Slide 13: Summary
Summary • Delivery/ outperformance vs. IPO expectations and timelines: - Expanded portfolio to three foundational products covering patient journey - Data expected Q1 2022 from validation studies for two lead products - Well powered studies (exceeded recruitment targets), with US and European patien
Slide 14: Appendix
<)clarava - (Ctuteva
Slide 15: Experienced Leadership for developing and commercializing kidney transplants assays
Experienced Leadership for developing and commercializing kidney transplants assays Julian Baines Sir Ian Carruthers Non-executive Chairman Senior Independent EKF Diagnostics, BBI Non-executive Director Chancellor UWE, Snr Director NHS Lorenzo Gallon Erik Lium Independent Non-executive Non-executive
Slide 16: Verici Dx - Kidney Transplant Diagnostics
Verici Dx - Kidney Transplant Diagnostics - RNA signature-based transplant technology producing high performing and actionable diagnostics - Enables accurate, data-driven support for critical decisions where there is now guesswork Overview - Large addressable market with recurring testing to address
Slide 17: Multinational Science Advisory Board of Key Opinion Leaders
Multinational Science Advisory Board of Key Opinion Leaders Lorenzo Gallon, MD (Chair) • Five (5) past presidents of major Tony Dorling, MD international Transplant organizations Richard Formica, MD (AST, TTS, ASTS) Roslyn Mannon, MD • Current President of American Peter Nickerson, MD Society of Tra
Slide 18: Large and growing issue has stimulated disruptive policy shifts
Large and growing issue has stimulated disruptive policy shifts About 300k globally people waiting for transplants • US Executive order 2019 “Advancing American Kidney Health” • 95,000 global kidney transplants p.a. 24,000 US / 25,000 Europe • Goal: to double supply of transplants • Average cost of
Slide 19: Critical need for personalized diagnostic information
Critical need for personalized diagnostic information What is the risk of Is the graft being rejected rejection? or damaged? Current practice: Current practice: Standard of Care Broad Clinical Factors/Score • Misses 30% of all cases • Too general and Therapeutic Dilemma largely ignored Competitive t
Slide 20: Slide 20